Imaging Endpoints (IE), a global leader in oncology imaging CRO technologies, has filed a provisional patent for its AI-enhanced Imaging Review Charter (AIRC) System™, a platform designed to modernize how clinical trial imaging is planned, reviewed, and optimized. The system aims to set a new industry standard for tailoring IRCs (Imaging Review Charters) to the unique requirements of each oncology trial.
Oncology clinical trials depend heavily on precise imaging protocols, and Imaging Endpoints has built a reputation for optimizing image acquisition and analysis to meet regulatory expectations. The company reports a 95% marketing approval success rate across more than 200 regulatory submissions, demonstrating the impact of its scientific rigor.
The AIRC System leverages AI to tackle long-standing challenges in trial imaging, including assimilating diverse datasets, recommending trial-specific modifications to published oncology criteria, and ensuring regulatory alignment with the FDA, EMA, and other global agencies. The platform is designed to accelerate trial setup while improving the quality and clarity of imaging charters.
Key features of the AIRC System include:
- Dynamic Customization: Integrates industry standards, published oncology criteria, IE’s proprietary analysis library, and study protocol data to generate trial-specific IRCs.
- Criteria Optimization: Uses the largest dataset and advanced analytics to identify necessary clarifications or modifications that enhance image acquisition and analysis for each trial.
- Enhanced Regulatory Compliance: Aligns IRCs with global regulatory requirements, standards, and recent agency guidance, streamlining both sponsor and agency reviews.
- Increased Efficiency: AI compiles and synthesizes data for IE’s physicians, scientific staff, and regulatory experts, reducing trial setup time and enhancing outcome reliability.
By combining AI-driven customization with IE’s deep domain expertise, the AIRC System represents a significant step toward more intelligent, efficient, and compliant oncology trial imaging. In an industry where delays can cost millions and regulatory scrutiny is intense, tools like this could redefine best practices for clinical imaging operations.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
